Welcome to the Mississippi Board of Pharmacy

The Mississippi Board of Pharmacy was established by legislative action in 1920. The mission of the Board is to protect and promote the health of Mississippi citizens by regulating and controlling the practice of pharmacy and the distribution of prescription drugs and devices. Our Board is comprised of seven pharmacist members, all appointed by the Governor. They are assisted by administrative staff headed by an Executive Director appointed by the Board.

NEWS AND EVENTS

Pharmacy Technician Certification 2021 | 2/11/2021

Pharmacy Technician Verification | 11/17/2020

Please note:

A Pharmacy Technician's application status can be tracked via the Licensing Gateway by the employer. Log in to the Gateway and access the facility record and view the employee's status.

Criminal Background Processing Change | 9/24/2020

For application purposes, you must request a standard FBI fingerprint card, form No. FD-258 used by the FBI for noncriminal fingerprinting from the Mississippi Board of Pharmacy. No other cards will be accepted. All completed cards must be mailed directly to:

Mississippi Department of Public Safety

Criminal Information Center

Applicant Processing

PO Box 958

Jackson, MS 39205-0958

UPDATED: Chloroquine and Hydroxychloroquine Information | 8/4/2020

It has come to our attention that there is some confusion over prescribing and dispensing chloroquine and hydroxychloroquine. The Board of Pharmacy did not restrict the usage of these medications. At the time of the previous guidance issued, there was a shortage, and many hospitals were using this medication as a key therapy.

As current efforts are underway to combat the COVID-19 pandemic, concern has been reported on the issuance of prescriptions and dispensing of hydroxychloroquine and chloroquine by pharmacies for prevention and treatment of COVID-19. The Board of Pharmacy has no purview over medications that a provider prescribes. Pharmacists should exercise caution dispensing these medications in a community setting.

At present, the FDA has not approved the use of chloroquine or hydroxychloroquine for COVID-19 prophylaxis or treatment. The prescribing physician should monitor a patient’s care.

Medication side effects, drug interactions, contraindications and laboratory monitoring requirements should also be considered when dispensing these medications for the treatment of COVID-19. There is a potential for toxicity. Meeting those monitoring needs for patients could be limited.

Pharmacists and prescribers must also consider that patients currently taking hydroxychloroquine for FDA approved indications could be affected by this prescribing. Pharmacists should monitor supplies of chloroquine and hydroxychloroquine for medication availability.

Providers prescribing hydroxychloroquine to patients for other indications (i.e., lupus, rheumatoid arthritis) are encouraged to note the indication on any new prescription issued.

Please note, pharmacists are encouraged to use their professional judgement and as always, are allowed to deny prescriptions based on this judgement as necessary.

This is a constantly evolving situation. As additional data is available, current information could be subject to change. Please continue to check your email from the Mississippi Board of Pharmacy and our website, www.mbp.ms.gov, for updated information pertaining to COVID-19.

Sincerely,

Jillian Foster

President

Mississippi Board of Pharmacy

Susan McCoy

Executive Director

Mississippi Board of Pharmacy

Amending or Creating a New Regulation | 8/3/2020

Curious about how regulations are amended or created? Check out this diagram!